Fedovapagon

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameFedovapagon
Drug Alias Name非多伐贡FedovapagonumFE-106483VT483VA483 +[6] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionVasopressin V2 receptor agonists
TargetsVasopressin V2 receptor
Therapy Area/IndicationsNocturiaProstatic Hyperplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVantia LtdFerring Bv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVantia Ltd
Active IndicationsN/A
Inactive IndicationsNocturiaProstatic Hyperplasia

Other Information

ATC CodeN/A
Related LinksN/A